Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
January 13 2022 - 9:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major
potential value drivers for 2022 at this morning’s presentation at
the 40th Annual J.P. Morgan Healthcare Conference.
Lexicon submitted a new drug application (NDA)
to the U.S. Food and Drug Administration (FDA) in December 2021 for
the approval of sotagliflozin to reduce the risk of cardiovascular
death, hospitalization for heart failure, and urgent visits for
heart failure in adult patients with type 2 diabetes. In the NDA,
Lexicon is seeking a potentially unique label addressing recent and
worsening heart failure, based on the landmark SOLOIST-WHF study.
Importantly, the proposed NDA label encompasses patients across the
spectrum of left ventricular ejection fraction (LVEF). If approved,
Lexicon expects to commercially launch sotagliflozin in the United
States in the second half of 2022. Lexicon will outline additional
details and information about its commercial strategy in today’s
presentation.
In addition, Lexicon is looking forward to
near-term results from two Phase 2 proof-of-concept studies of
LX9211 in neuropathic pain. LX9211 is a potent, orally delivered,
selective small molecule inhibitor of adaptor associated kinase 1
(AAK1), a novel target first identified using Lexicon’s technology
platform as having promise for the treatment of neuropathic pain.
Results from these two studies are expected in the first half of
2022.
“We enter 2022 focused on these two objectives
that each have the potential to drive major value for our
stakeholders,” said Lonnel Coats, Lexicon’s chief executive
officer. “Both heart failure and neuropathic pain represent
multi-billion dollar markets of high unmet need and, if successful,
we believe that both of these investigational products have
blockbuster potential.”
Today at 10:30 a.m. ET, Mr. Coats will present
virtually at the 40th Annual J.P. Morgan Healthcare Conference. A
webcast of the event will be available in the “Events” section of
the Lexicon website at www.lexpharma.com.
About Lexicon
Pharmaceuticals
Lexicon is a biopharmaceutical company with a
mission of pioneering medicines that transform patients’ lives.
Through its Genome5000™ program, Lexicon scientists studied the
role and function of nearly 5,000 genes and identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. Lexicon advanced
one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical
development in neuropathic pain, heart failure, diabetes and
metabolism and other indications. For additional information,
please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, including the
clinical development of, regulatory filings for, and potential
therapeutic and commercial potential of sotagliflozin, LX9211 and
its other potential drug candidates. In addition, this press
release also contains forward looking statements relating to
Lexicon’s growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully conduct preclinical and clinical development and
obtain necessary regulatory approvals of sotagliflozin, LX9211 and
its other potential drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2020, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Investor RelationsLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024